Cancer-specific T-cell receptors

1. A peptide comprising the amino acid sequence of SEQ ID NO: 80, SEQ ID NO: 77, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 84, or SEQ ID NO: 85.

2. The peptide of claim 1 comprising the amino acid sequence of SEQ ID NO: 80.

3. The peptide of claim 1 , wherein the amino acid sequence of the peptide consists of the amino acid sequence of SEQ ID NO: 80, SEQ ID NO: 77, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 84, or SEQ ID NO: 85.

4. The peptide of claim 3 , wherein the amino acid sequence of the peptide consists of the amino acid sequence of SEQ ID NO: 80.

5. The peptide of claim 1 , wherein the peptide is presented by a human leukocyte antigen class I A (HLA-A) molecule, optionally, wherein the HLA-A molecule is HLA-A2, HLA-A24, HLA-A1, or HLA-A3.

6. A pharmaceutical composition comprising the peptide of claim 1 .

7. A vaccine comprising the peptide of claim 1 .

8. An immunogenic agent comprising the peptide of claim 1 .

9. A combination therapeutic comprising the peptide of claim 1 , and a further therapeutic agent.

10. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the peptide of claim 1 .

11. The method of claim 10 , wherein the cancer is nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia, T-cell/lymphoma, blood cancer, tonsil, spleen cancer, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumour, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, muscle cancer, Paget's disease, cervical cancer, rectal cancer, esophagus cancer, gall bladder cancer, cholangioma cancer, head cancer, eye cancer, nasopharynx cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, skin cancer, mesothelioma, myeloma, multiple myeloma, ovarian cancer, endocrine cancer, glucagonoma, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer, or tonsil cancer.

12. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the peptide of claim 3 .

13. The method of claim 12 , wherein the cancer is nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia, T-cell/lymphoma, blood cancer, tonsil, spleen cancer, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, glioma, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumour, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, muscle cancer, Paget's disease, cervical cancer, rectal cancer, esophagus cancer, gall bladder cancer, cholangioma cancer, head cancer, eye cancer, nasopharynx cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, skin cancer, mesothelioma, myeloma, multiple myeloma, ovarian cancer, endocrine cancer, glucagonoma, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer, or tonsil cancer.

14. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the peptide of claim 4 .

15. The peptide of claim 1 comprising the amino acid sequence of SEQ ID NO: 77.

16. A vector encoding the peptide of claim 1 .

17. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the vector of claim 16 .

18. A vector encoding the peptide of claim 3 .

19. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject the vector of claim 18 .